Physician profile
Mohammed M Ali
NPI 1053405506
$2,444.29
in general payments reported to CMS, 2019-2025
19 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $315 · 2021: $241 · 2022: $600 · 2023: $331 · 2024: $81.61 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $769.62 | 2019-2024 | Farxiga, Airsupra |
| Alkermes, INC. | $285.99 | 2019 | |
| Lilly USA, LLC | $261.71 | 2019-2023 | Mounjaro |
| Corcept Therapeutics | $245.98 | 2019-2022 | |
| Abbvie INC. | $188.19 | 2022-2024 | Vraylar |
| Indivior INC. | $163.38 | 2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $110.60 | 2019-2021 | |
| Novo Nordisk INC | $92.89 | 2020-2023 | Rybelsus |
| Janssen Pharmaceuticals, INC | $69.66 | 2019-2022 | |
| Exact Sciences Corporation | $53.33 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $44.95 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.34 | 2019 | |
| Eisai INC. | $21.15 | 2021 | |
| Noven Therapeutics, LLC | $21.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.48 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.22 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.20 | 2019 | |
| Glaxosmithkline, LLC. | $15.20 | 2019 | |
| Lucid Diagnostics INC. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.